Table 1.

Comparison of gene centering with a subgroup-specific strategy on the UNC prototypic tumor set ^a

			Prediction (%)
Dataset	Subgroup	Gene-centering method	Basal-like	HER2-enriched	LumA	LumB	Normal-like
Prototypic basal	Basal-like	Standard	12 (21.1)	8 (14)	17 (29.8)	16 (28.1)	4 (7)
(n = 57)		Subgroup-specific	56 (98.2)	0 (0)	0 (0)	0 (0)	1 (1.8)
Prototypic HER2	Her2-enriched	Standard	8 (22.9)	7 (20)	10 (28.6)	6 (17.1)	4 (11.4)
(n = 35)		Subgroup-specific	2 (5.7)	27 (77.1)	1 (2.9)	5 (14.3)	0 (0)
Prototypic LumA	Luminal A	Standard	7 (30.4)	1 (4.3)	6 (26.1)	3 (13)	6 (26.1)
(n = 23)		Subgroup-specific	0 (0)	0 (0)	21 (91.3)	1 (4.3)	1 (4.3)
Prototypic LumB	Luminal B	Standard	2 (16.7)	3 (25)	3 (25)	2 (16.7)	2 (16.7)
(n = 12)		Subgroup-specific	0 (0)	0 (0)	0 (0)	12 (100)	0 (0)
Prototypic normal	Normal-like	Standard	2 (16.7)	2 (16.7)	2 (16.7)	2 (16.7)	4 (33.3)
(n = 12)		Subgroup-specific	0 (0)	0 (0)	0 (0)	0 (0)	12 (100)

^aHER2, Human epidermal growth factor receptor 2; LumA, Luminal A; LumB, Luminal B; UNC, University of North Carolina.